1 / 8

Anti-lymphocyte Tumor Mechanism of CD19-CART Cells

Lymphoid malignancies include lymphocytic leukemia and lymphoma, which are tumors that occur on lymphocytes such as B cells, T cells, and NK cells. At present, there are many difficulties in its treatment, which are related to the recurrence and refractory of the diseases in the clinic. In the past 10 years, great progress has been made in the clinical treatment of lymphatic system tumors. Anti-CD20 monoclonal antibodies have been widely used in CD20-positive B-cell non-Hodgkin's lymphomas, and have achieved good results, becoming the first-line clinical application. However, since the cell surface of lymphoma and acute-chronic lymphocytic leukemia often has only CD19 antigen, an anti-CD20 antibody such as rituximab has no obvious therapeutic effect on it, therefore there is an urgent need for a new treatment method to improve the cure rate of lymphoma and acute and chronic lymphoma.

bellasmith123
Download Presentation

Anti-lymphocyte Tumor Mechanism of CD19-CART Cells

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Anti-lymphocyte Tumor Mechanism of CD19-CART Cells www.creative-biolabs.com/car-t

  2. Lymphoid malignancies Chart Lymphoid malignancies include lymphocytic leukemia and lymphoma, which are tumors that occur on lymphocytes such as B cells, T cells, and NK cells. At present, there are many difficulties in its treatment, which are related to the recurrence and refractory of the diseases in the clinic. In the past 10 years, great progress has been made in the clinical treatment of lymphatic system tumors. Anti-CD20 monoclonal antibodies have been widely used in CD20-positive B-cell non-Hodgkin's lymphomas, and have achieved good results, becoming the first-line clinical application. However, since the cell surface of lymphoma and acute-chronic lymphocytic leukemia often has only CD19 antigen, an anti-CD20 antibody such as rituximab has no obvious therapeutic effect on it, therefore there is an urgent need for a new treatment method to improve the cure rate of lymphoma and acute and chronic lymphoma.

  3. Chimeric antigen receptor T cell Chart Chimeric antigen receptor T cell immunotherapy (CART) cells help T lymphocytes express a specific CAR through genetic modification. The cell can specifically recognize the target antigen and kill target cells. CART cells have a high affinity for specific tumor antigens, so that they can efficiently kill tumor cells expressing the antigen. CD19 is specifically expressed on the surface of B-lymphocytes in different stages of differentiation. CD19 antigen is expressed in more than 95% of B-cell lymphomas and B-lymphocytic leukemia. The establishment of CART cells recognizing CD19 chimeric antigen receptors that can achieve the therapeutic purpose of B lymphocyte tumors.

  4. Cytotoxic T cells are CD8+ T lymphocytes activated by antigen presenting cells (APCs). Studies have shown that activation of T cells relies on activation of dual signaling pathways to proliferate into cytotoxic T cells. Where the first signalling pathway is the combination of the MHC molecule-antigenic peptide complex on APCs and T cell receptors, and the second signaling pathway is the B7 co-stimulatory molecule on the APC surface binds to the CD28 molecule on the T cell surface. When a cytotoxic T cell meets with a tumor cell carrying the same MHC molecule-antigen peptide complex, release of perforin can result in cell lysis. In addition, granzymes can be secreted to induce apoptosis in target cells.

  5. CAR T design Chart The key to CAR T design is to select the appropriate tumor antigen as a target. Since CD19 is expressed at various stages of differentiation of B lymphocytes, and other non-B cells do not have CD19 expression, CAR for CD19 is currently the most studied CART cell in clinical practice.

  6. About Creative Biolabs As a global company, Creative Biolabs has more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, we are the established leading expert in TCR and CAR T&NK cell immune therapy development, as we offer the one-stop custom services that cover the entire new drug development pipeline. Additionally, we also offer an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, we have built up a unique unparalleled CAR construction and production platform for all four CAR generations.

  7. Contact us 45-1 Ramsey Road, Shirley, NY 11967, USA Email: marketing@creative-biolabs.com

  8. Thank you

More Related